Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9bln
PHOTO
Japan's Astellas Pharma said on Monday it had fully acquired drugmaker IVERIC Bio Inc , through Berry Merger Sub, Inc, a wholly-owned subsidiary of Astellas US Holding, Inc.
Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9 billion.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Kim Coghill)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
